Middle East Liquid Biopsy Market Size, Share & Trends Analysis Report By Biomarker, By Technology, By Sample Type, By Application, By Clinical Application, By End Use, By Product, By Region, And Segment Forecasts, 2025 - 2033
Description
Middle East Liquid Biopsy Market Summary
The Middle East liquid biopsy market size was valued at USD 104.76 million in 2024 and is projected to reach USD 233.95 billion by 2033, growing at a CAGR of 9.28% from 2025 to 2033. The market is driven by increased emphasis on early detection and population-level screening initiatives across the Middle East, fueled by rising cancer prevalence.
For example, in December 2024, Abu Dhabi launched a new blood-based colon cancer test as part of a proactive strategy to improve early detection and survival rates. The program addresses a significant gap in early diagnosis.
In addition, according to data from 2023, 67% of cases of colorectal cancer in Abu Dhabi were discovered at a late stage, which limited treatment options and decreased survival rates. The program, which offers a non-invasive alternative to traditional screening methods, is expected to enhance patient participation and support the UAE broader efforts to improve early detection and outcomes. The market for non-invasive early detection technologies is growing beyond advanced-stage cancer, and the Middle East liquid biopsy market is being boosted by new blood-based screening programs for colorectal and lung cancer.
Rising government and health-system adoption, supported by national pilot programs, is fueling market growth by encouraging wider testing and strengthening healthcare readiness. For instance, in June 2025, M42 entered into a strategic partnership with AstraZeneca and SOPHiA GENETICS to bring advanced liquid biopsy testing to the UAE, supporting cancer diagnosis, guiding treatment choices, and enabling quicker and more accurate biomarker analysis across various cancer types. Through this collaboration, M42 adopted SOPHiA GENETICS’ MSK-ACCESS, powered by the SOPHiA DDM platform, within its testing network, allowing for non-invasive genomic profiling using a simple blood sample.
Government-supported screening initiatives and hospital-led validation studies, such as evaluation by Cleveland Clinic Abu Dhabi and the Abu Dhabi colorectal cancer program, are accelerating early clinical adoption, increasing in test reliability, and moving reimbursement awareness forward throughout the region. The new testing initiative will initially focus on lung, ovarian, breast, colorectal, and pancreatic cancers, among others, addressing some of the region's most pressing cancer issues. Over the next year, the partnership will expand access to liquid biopsy testing to selected major hospitals in the UAE, providing patients with faster and less invasive biomarker insights than traditional tissue biopsies, while also increasing the country's testing capacity and cancer diagnostic capabilities.
Moreover, regional pharmaceutical and medical groups are entering exclusive distribution and partnership agreements that expand commercial availability and strengthen regional laboratory services. For instance, in June 2022, Imagia Canexia Health (Canada) signed a Memorandum of Understanding (MOU) with the Kingdom of Saudi Arabia to distribute its liquid biopsy testing products throughout Saudi Arabia and Middle East region. The company offers liquid biopsy solutions for therapy selection and patient monitoring that can be performed at or near the point of care, eliminating the need to send samples to international centralized laboratories. This approach allows cancer patients all across the region to access advanced precision oncology treatments at a lower cost and faster turnaround time. Such collaborations remove key access barriers, standardize test delivery across local markets, and accelerate the liquid biopsy market's growth.
Furthermore, growing strategic partnerships and commercial rollouts are fueling the Middle East liquid biopsy market, enabling global companies to work closely with regional clinical stakeholders. For instance, in January 2024, Hikma Pharmaceuticals PLC (UK) entered into an agreement with Guardant Health, Inc. (US) for commercialization and marketing of Guardant Health’s portfolio of liquid and tissue biopsy tests for cancer screening, recurrence monitoring and tumor mutation profiling across all solid cancers in the Middle East. In addition, the portfolio features tests such as Shield for early cancer screening, Guardant Reveal for detecting minimal residual disease and tracking recurrence, and Guardant360 along with Guardant360 TissueNext for comprehensive genomic profiling (CGP) across all solid tumors. These alliances help to launch and expand liquid biopsy products across the Middle East, improving accessibility, streamlining distribution, and significantly accelerating market entry and scale-up.
Middle East Liquid Biopsy Market Report Segmentation
This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For the purpose of this report, Grand View Research has segmented the liquid biopsy market on the basis product, sample type, technology, biomarker, application, clinical application, end use, and country.
The Middle East liquid biopsy market size was valued at USD 104.76 million in 2024 and is projected to reach USD 233.95 billion by 2033, growing at a CAGR of 9.28% from 2025 to 2033. The market is driven by increased emphasis on early detection and population-level screening initiatives across the Middle East, fueled by rising cancer prevalence.
For example, in December 2024, Abu Dhabi launched a new blood-based colon cancer test as part of a proactive strategy to improve early detection and survival rates. The program addresses a significant gap in early diagnosis.
In addition, according to data from 2023, 67% of cases of colorectal cancer in Abu Dhabi were discovered at a late stage, which limited treatment options and decreased survival rates. The program, which offers a non-invasive alternative to traditional screening methods, is expected to enhance patient participation and support the UAE broader efforts to improve early detection and outcomes. The market for non-invasive early detection technologies is growing beyond advanced-stage cancer, and the Middle East liquid biopsy market is being boosted by new blood-based screening programs for colorectal and lung cancer.
Rising government and health-system adoption, supported by national pilot programs, is fueling market growth by encouraging wider testing and strengthening healthcare readiness. For instance, in June 2025, M42 entered into a strategic partnership with AstraZeneca and SOPHiA GENETICS to bring advanced liquid biopsy testing to the UAE, supporting cancer diagnosis, guiding treatment choices, and enabling quicker and more accurate biomarker analysis across various cancer types. Through this collaboration, M42 adopted SOPHiA GENETICS’ MSK-ACCESS, powered by the SOPHiA DDM platform, within its testing network, allowing for non-invasive genomic profiling using a simple blood sample.
Government-supported screening initiatives and hospital-led validation studies, such as evaluation by Cleveland Clinic Abu Dhabi and the Abu Dhabi colorectal cancer program, are accelerating early clinical adoption, increasing in test reliability, and moving reimbursement awareness forward throughout the region. The new testing initiative will initially focus on lung, ovarian, breast, colorectal, and pancreatic cancers, among others, addressing some of the region's most pressing cancer issues. Over the next year, the partnership will expand access to liquid biopsy testing to selected major hospitals in the UAE, providing patients with faster and less invasive biomarker insights than traditional tissue biopsies, while also increasing the country's testing capacity and cancer diagnostic capabilities.
Moreover, regional pharmaceutical and medical groups are entering exclusive distribution and partnership agreements that expand commercial availability and strengthen regional laboratory services. For instance, in June 2022, Imagia Canexia Health (Canada) signed a Memorandum of Understanding (MOU) with the Kingdom of Saudi Arabia to distribute its liquid biopsy testing products throughout Saudi Arabia and Middle East region. The company offers liquid biopsy solutions for therapy selection and patient monitoring that can be performed at or near the point of care, eliminating the need to send samples to international centralized laboratories. This approach allows cancer patients all across the region to access advanced precision oncology treatments at a lower cost and faster turnaround time. Such collaborations remove key access barriers, standardize test delivery across local markets, and accelerate the liquid biopsy market's growth.
Furthermore, growing strategic partnerships and commercial rollouts are fueling the Middle East liquid biopsy market, enabling global companies to work closely with regional clinical stakeholders. For instance, in January 2024, Hikma Pharmaceuticals PLC (UK) entered into an agreement with Guardant Health, Inc. (US) for commercialization and marketing of Guardant Health’s portfolio of liquid and tissue biopsy tests for cancer screening, recurrence monitoring and tumor mutation profiling across all solid cancers in the Middle East. In addition, the portfolio features tests such as Shield for early cancer screening, Guardant Reveal for detecting minimal residual disease and tracking recurrence, and Guardant360 along with Guardant360 TissueNext for comprehensive genomic profiling (CGP) across all solid tumors. These alliances help to launch and expand liquid biopsy products across the Middle East, improving accessibility, streamlining distribution, and significantly accelerating market entry and scale-up.
Middle East Liquid Biopsy Market Report Segmentation
This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For the purpose of this report, Grand View Research has segmented the liquid biopsy market on the basis product, sample type, technology, biomarker, application, clinical application, end use, and country.
- Product Outlook (Revenue, USD Million, 2021 - 2033)
- Instruments
- Consumables Kits and Reagents
- Software and Services
- Sample Type Outlook (Revenue, USD Million, 2021 - 2033)
- Blood Sample
- Others
- Technology Outlook (Revenue, USD Million, 2021 - 2033)
- Multi-gene parallel Analysis (NGS)
- Single Gene Analysis (PCR Microarrays)
- Biomarker Outlook (Revenue, USD Million, 2021 - 2033)
- Circulating Nucleic Acids
- CTC
- Exosomes/Microvesicles
- Circulating Proteins
- Application Outlook (Revenue, USD Million, 2021 - 2033)
- Cancer
- Lung Cancer
- Prostate Cancer
- Breast Cancer
- Colorectal Cancer
- Leukemia
- Gastrointestinal Cancer
- Others
- Reproductive Health
- Others
- Clinical Application Outlook (Revenue, USD Million, 2021 - 2033)
- Therapy Selection
- Treatment Monitoring
- Early Cancer Screening
- Recurrence Monitoring
- Others
- End Use Outlook (Revenue, USD Million, 2021 - 2033)
- Hospitals and Laboratories
- Specialty Clinics
- Academic and Research Centers
- Others
- Country Outlook (Revenue, USD Million, 2021- 2033)
- Saudi Arabia
- UAE
- Kuwait
- Oman
- Qatar
- Rest of Middle East
Table of Contents
150 Pages
- Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Market Definitions
- 1.2.1. Product Segment
- 1.2.2. Sample Type Segment
- 1.2.3. Technology Segment
- 1.2.4. Biomarker Segment
- 1.2.5. Application Segment
- 1.2.6. Clinical Application Segment
- 1.2.7. End-use Segment
- 1.3. Information analysis
- 1.3.1. Market formulation & data visualization
- 1.4. Data validation & publishing
- 1.5. Information Procurement
- 1.5.1. Primary Research
- 1.6. Information or Data Analysis
- 1.7. Market Formulation & Validation
- 1.8. Market Biomarker
- 1.9. Total Market: CAGR Calculation
- 1.10. Objectives
- 1.10.1. Objective 1
- 1.10.2. Objective 2
- Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Snapshot
- 2.3. Competitive Insights Landscape
- Chapter 3. Middle East Liquid Biopsy Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook.
- 3.2. Market Dynamics
- 3.2.1. Market driver analysis
- 3.2.1.1. Increased emphasis on early detection and population-level screening programs
- 3.2.1.2. Growing strategic partnerships and commercial rollouts
- 3.2.1.3. Rising government and health system adoption
- 3.2.1.4. Increasing agreements among pharmaceutical and medical groups
- 3.2.2. Market restraint analysis
- 3.2.2.1. High cost of liquid biopsy tests and technologies
- 3.2.2.2. Limited regulatory frameworks and reimbursement challenges in emerging markets
- 3.3. Middle East Liquid Biopsy Market Analysis Tools
- 3.3.1. Industry Analysis - Porter’s
- 3.3.2. PESTEL Analysis
- Chapter 4. Middle East Liquid Biopsy Market: Product Estimates & Trend Analysis
- 4.1. Segment Dashboard
- 4.2. Middle East Antinuclear Market: Product Movement Analysis
- 4.3. Middle East liquid biopsy market Size & Trend Analysis, By Product, 2021 to 2033 (USD Million)
- 4.4. Instruments
- 4.4.1. Instruments market estimates and forecasts 2021 to 2033 (USD Million)
- 4.5. Consumables Kits and Reagents
- 4.5.1. Consumables kits and reagents market estimates and forecasts 2021 to 2033 (USD Million)
- 4.6. Software and Services
- 4.6.1. Software and services market estimates and forecasts 2021 to 2033 (USD Million)
- Chapter 5. Middle East Liquid Biopsy Market: Sample Type Estimates & Trend Analysis
- 5.1. Segment Dashboard
- 5.2. Middle East Liquid Biopsy Market, Sample Type Movement Analysis
- 5.3. Middle East Liquid Biopsy Market Size & Trend Analysis, By Sample Type, 2021 to 2033 (USD Million)
- 5.4. Blood Sample
- 5.4.1. Blood sample market estimates and forecasts 2021 to 2033 (USD Million)
- 5.5. Others
- 5.5.1. Others market estimates and forecasts 2021 to 2033 (USD Million)
- Chapter 6. Middle East Liquid Biopsy Market: Technology Estimates & Trend Analysis
- 6.1. Segment Dashboard
- 6.2. Middle East Liquid Biopsy Market, Technology Movement Analysis
- 6.3. Middle East Liquid Biopsy Market Size & Trend Analysis, By Biomarker, 2021 to 2033 (USD Million)
- 6.4. Multi-gene parallel Analysis (NGS)
- 6.4.1. Multi-gene parallel analysis (NGS)market estimates and forecasts 2021 to 2033 (USD Million)
- 6.5. Single Gene Analysis (PCR Microarrays)
- 6.5.1. Single gene analysis (PCR microarrays) market estimates and forecasts 2021 to 2033 (USD Million)
- Chapter 7. Middle East Liquid Biopsy Market: Biomarker Estimates & Trend Analysis
- 7.1. Segment Dashboard
- 7.2. Middle East Liquid Biopsy Market Biomarker Movement Analysis
- 7.2.1. Middle East Liquid Biopsy Market & Trend Analysis, by Biomarker, 2021 to 2033 (USD Million)
- 7.3. Circulating Nucleic Acids
- 7.3.1. Circulating Nucleic Acids market estimates and forecasts 2021 to 2033 (USD Million)
- 7.4. CTC
- 7.4.1. CTC market estimates and forecasts 2021 to 2033 (USD Million)
- 7.5. Exosomes/Microvesicles
- 7.5.1. Exosomes/microvesicles market estimates and forecasts 2021 to 2033 (USD Million)
- 7.6. Circulating Proteins
- 7.6.1. Circulating proteins market estimates and forecasts 2021 to 2033 (USD Million)
- Chapter 8. Middle East Liquid Biopsy Market: Application Estimates & Trend Analysis
- 8.1. Segment Dashboard
- 8.2. Middle East Liquid Biopsy Market Application Movement Analysis
- 8.2.1. Middle East Liquid Biopsy Market & Trend Analysis, by Application, 2021 to 2033 (USD Million)
- 8.3. Cancer
- 8.3.1. Cancer market estimates and forecasts 2021 to 2033 (USD Million)
- 8.3.2. Lung Cancer
- 8.3.2.1. Lung market estimates and forecasts 2021 to 2033 (USD Million)
- 8.3.3. Prostate Cancer
- 8.3.3.1. Prostate cancer market estimates and forecasts 2021 to 2033 (USD Million)
- 8.3.4. Breast Cancer
- 8.3.4.1. Breast cancer market estimates and forecasts 2021 to 2033 (USD Million)
- 8.3.5. Colorectal Cancer
- 8.3.5.1. Colorectal cancer market estimates and forecasts 2021 to 2033 (USD Million)
- 8.3.6. Leukemia
- 8.3.6.1. Leukemia market estimates and forecasts 2021 to 2033 (USD Million)
- 8.3.7. Gastrointestinal Cancer
- 8.3.7.1. Gastrointestinal cancer market estimates and forecasts 2021 to 2033 (USD Million)
- 8.3.8. Others
- 8.3.8.1. Others market estimates and forecasts 2021 to 2033 (USD Million)
- 8.4. Reproductive Health
- 8.4.1. Reproductive health market estimates and forecasts 2021 to 2033 (USD Million)
- 8.5. Others
- 8.5.1. Others market estimates and forecasts 2021 to 2033 (USD Million)
- Chapter 9. Middle East Liquid Biopsy Market: Clinical Application Estimates & Trend Analysis
- 9.1. Segment Dashboard
- 9.2. Middle East Liquid Biopsy Market Clinical Application Movement Analysis
- 9.2.1. Middle East Liquid Biopsy Market & Trend Analysis, by Clinical Application, 2021 to 2033 (USD Million)
- 9.3. Therapy Selection
- 9.3.1. Therapy selection market estimates and forecasts 2021 to 2033 (USD Million)
- 9.4. Treatment Monitoring
- 9.4.1. Treatment monitoring market estimates and forecasts 2021 to 2033 (USD Million)
- 9.5. Early Cancer Screening
- 9.5.1. Early cancer screening market estimates and forecasts 2021 to 2033 (USD Million)
- 9.6. Recurrence Monitoring
- 9.6.1. Recurrence monitoring market estimates and forecasts 2021 to 2033 (USD Million)
- 9.7. Others
- 9.7.1. Others market estimates and forecasts 2021 to 2033 (USD Million)
- Chapter 10. Middle East Liquid Biopsy Market: End-use Estimates & Trend Analysis
- 10.1. Segment Dashboard
- 10.2. Middle East Liquid Biopsy Market End-use Movement Analysis
- 10.2.1. Middle East Liquid Biopsy Market & Trend Analysis, by End-use, 2021 to 2033 (USD Million)
- 10.3. Hospitals and Laboratories
- 10.3.1. Hospitals and laboratories market estimates and forecasts 2021 to 2033 (USD Million)
- 10.4. Specialty Clinics
- 10.4.1. Specialty clinics market estimates and forecasts 2021 to 2033 (USD Million)
- 10.5. Academic and Research Center
- 10.5.1. Academic and research center market estimates and forecasts 2021 to 2033 (USD Million)
- 10.6. Others
- 10.6.1. Others market estimates and forecasts 2021 to 2033 (USD Million)
- Chapter 11. Middle East Liquid Biopsy Market: Regional Estimates & Trend Analysis
- 11.1. Regional Dashboard
- 11.2. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
- 11.3. Middle East
- 11.3.1. Saudi Arabia
- 11.3.1.1. Key country dynamics
- 11.3.1.2. Regulatory framework/ reimbursement structure
- 11.3.1.3. Competitive scenario
- 11.3.1.4. Oman market estimates and forecasts 2021 to 2033 (USD Million)
- 11.3.2. UAE
- 11.3.2.1. Key country dynamics
- 11.3.2.2. Regulatory framework/ reimbursement structure
- 11.3.2.3. Competitive scenario
- 11.3.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
- 11.3.3. Kuwait
- 11.3.3.1. Key country dynamics
- 11.3.3.2. Regulatory framework/ reimbursement structure
- 11.3.3.3. Competitive scenario
- 11.3.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
- 11.3.4. Oman
- 11.3.4.1. Key country dynamics
- 11.3.4.2. Regulatory framework/ reimbursement structure
- 11.3.4.3. Competitive scenario
- 11.3.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)
- 11.3.5. Qatar
- 11.3.5.1. Key country dynamics
- 11.3.5.2. Regulatory framework/ reimbursement structure
- 11.3.5.3. Competitive scenario
- 11.3.5.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)
- 11.3.6. Rest of Middle East
- 11.3.6.1. Key country dynamics
- 11.3.6.2. Regulatory framework/ reimbursement structure
- 11.3.6.3. Competitive scenario
- 11.3.6.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)
- Chapter 12. Competitive Landscape
- 12.1. Company/Competition Categorization
- 12.2. Strategy Mapping
- 12.3. Company Market Share Analysis, 2024
- 12.4. List of Key Certification Providers/Scheme Owners
- 12.5. Company Profiles/Listing
- 12.5.1. CelLBxHealth
- 12.5.1.1. Company overview
- 12.5.1.2. Financial performance
- 12.5.1.3. Product benchmarking
- 12.5.1.4. Strategic initiatives
- 12.5.2. Oncimmune Holdings PLC
- 12.5.2.1. Company overview
- 12.5.2.2. Financial performance
- 12.5.2.3. Product benchmarking
- 12.5.2.4. Strategic initiatives
- 12.5.3. Guardant Health, Inc.
- 12.5.3.1. Company overview
- 12.5.3.2. Financial performance
- 12.5.3.3. Product benchmarking
- 12.5.3.4. Strategic initiatives
- 12.5.4. Myriad Genetics, Inc.
- 12.5.4.1. Company overview
- 12.5.4.2. Financial performance
- 12.5.4.3. Product benchmarking
- 12.5.4.4. Strategic initiatives
- 12.5.5. Thermo Fisher Scientific, Inc.
- 12.5.5.1. Company overview
- 12.5.5.2. Financial performance
- 12.5.5.3. Product benchmarking
- 12.5.5.4. Strategic initiatives
- 12.5.6. F. Hoffmann-La Roche Ltd
- 12.5.6.1. Company overview
- 12.5.6.2. Financial performance
- 12.5.6.3. Product benchmarking
- 12.5.6.4. Strategic initiatives
- 12.5.7. QIAGEN
- 12.5.7.1. Company overview
- 12.5.7.2. Financial performance
- 12.5.7.3. Product benchmarking
- 12.5.7.4. Strategic initiatives
- 12.5.8. Illumina, Inc.
- 12.5.8.1. Company overview
- 12.5.8.2. Financial performance
- 12.5.8.3. Product benchmarking
- 12.5.8.4. Strategic initiatives
- 12.5.9. Thermo Fisher Scientific, Inc.
- 12.5.9.1. Company overview
- 12.5.9.2. Financial performance
- 12.5.9.3. Product benchmarking
- 12.5.9.4. Strategic initiatives
- 12.5.10. Epigenomics AG
- 12.5.10.1. Company overview
- 12.5.10.2. Financial performance
- 12.5.10.3. Product benchmarking
- 12.5.10.4. Strategic initiatives
- 12.5.11. NeoGenomics Laboratories
- 12.5.11.1. Company overview
- 12.5.11.2. Financial performance
- 12.5.11.3. Product benchmarking
- 12.5.11.4. Strategic initiatives
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.